BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

Compare

2,374 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMRN Analyst Ratings

Moderate Buy

8 Buy

5 Hold

0 Sell

Based on 13 analysts giving stock ratings to

BioMarin

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$86.58

▲(53.13% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $86.58 with a high forecast of $120.00 and a low forecast of $60.00. The average price target represents a 53.13% change from the last price of $56.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"$52","121":"$121","69.25":"$69.3","86.5":"$86.5","103.75":"$103.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$86.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,69.25,86.5,103.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.43,64.08923076923077,68.74846153846154,73.4076923076923,78.06692307692308,82.72615384615384,87.38538461538461,92.04461538461538,96.70384615384614,101.36307692307692,106.02230769230769,110.68153846153845,115.34076923076923,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.43,61.51846153846154,63.606923076923074,65.69538461538461,67.78384615384616,69.87230769230769,71.96076923076923,74.04923076923077,76.1376923076923,78.22615384615384,80.31461538461538,82.40307692307692,84.49153846153845,{"y":86.58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.43,59.473846153846154,59.51769230769231,59.56153846153846,59.605384615384615,59.64923076923077,59.69307692307692,59.73692307692308,59.78076923076923,59.824615384615385,59.86846153846154,59.91230769230769,59.956153846153846,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$86.58

Lowest Price Target$60.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eliana Merle

Barclays

$80

Buy

41.49%

Upside

Reiterated

01/27/26

BioMarin assumed with an Overweight at BarclaysBioMarin assumed with an Overweight at Barclays

Whitney Ijem

Canaccord Genuity

$84→$98

Buy

73.33%

Upside

Upgraded

01/20/26

BioMarin: Undervalued Growth Story Reinforced by Strategic Amicus Acquisition and Expanding Rare-Disease Franchise

Cory Kasimov

Evercore ISI

$110

Buy

94.55%

Upside

Reiterated

01/13/26

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Sami Corwin

William Blair

Hold

―

Reiterated

01/13/26

Balanced View on BioMarin: Solid Near-Term Guidance Offset by Voxzogo Competitive Risks and Roctavian Challenges, Supporting a Hold Rating

Yun Zhong

Wedbush

$94

Buy

66.25%

Upside

Reiterated

01/13/26

BioMarin: Sustained Double-Digit Growth Story Underpinned by Voxzogo Leadership, Advancing Rare-Disease Pipeline, and Accretive Amicus Acquisition

Phil Nadeau

TD Cowen

$120

Buy

112.24%

Upside

Reiterated

01/12/26

BioMarin: Buy Rating Reaffirmed on Strong 2025 Outlook, Promising Pipeline, and Accretive M&A

Luca Issi

RBC Capital

$66

Hold

16.73%

Upside

Reiterated

01/08/26

Analysts Conflicted on These Healthcare Names: Cormedix (NASDAQ: CRMD), BioMarin Pharmaceutical (NASDAQ: BMRN) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Joon Lee

Truist Financial

$80→$100

Buy

76.87%

Upside

Reiterated

12/23/25

Truist Financial Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Mitchell Kapoor

H.C. Wainwright

$55→$60

Hold

6.12%

Upside

Reiterated

12/22/25

BioMarin price target raised to $60 from $55 at H.C. WainwrightBioMarin price target raised to $60 from $55 at H.C. Wainwright

Jason Gerberry

Bank of America Securities

$102

Buy

80.40%

Upside

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Paul Matteis

Stifel Nicolaus

$61

Hold

7.89%

Upside

Assigned

12/19/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Pfizer (NYSE: PFE)

William Pickering

Bernstein

$88

Buy

55.64%

Upside

Reiterated

12/19/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Disc Medicine (NASDAQ: IRON) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Joseph Schwartz

Leerink Partners

$60

Hold

6.12%

Upside

Downgraded

12/03/25

BioMarin downgraded to Market Perform from Outperform at LeerinkBioMarin downgraded to Market Perform from Outperform at Leerink

Akash Tewari

Jefferies

$113

Buy

99.86%

Upside

Reiterated

10/28/25

Jefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Mohit Bansal

Wells Fargo

$90→$70

Buy

23.81%

Upside

Reiterated

10/28/25

BioMarin price target lowered to $70 from $90 at Wells FargoBioMarin price target lowered to $70 from $90 at Wells Fargo

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eliana Merle

Barclays

$80

Buy

41.49%

Upside

Reiterated

01/27/26

BioMarin assumed with an Overweight at BarclaysBioMarin assumed with an Overweight at Barclays

Whitney Ijem

Canaccord Genuity

$84→$98

Buy

73.33%

Upside

Upgraded

01/20/26

BioMarin: Undervalued Growth Story Reinforced by Strategic Amicus Acquisition and Expanding Rare-Disease Franchise

Cory Kasimov

Evercore ISI

$110

Buy

94.55%

Upside

Reiterated

01/13/26

Evercore ISI Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Sami Corwin

William Blair

Hold

―

Reiterated

01/13/26

Balanced View on BioMarin: Solid Near-Term Guidance Offset by Voxzogo Competitive Risks and Roctavian Challenges, Supporting a Hold Rating

Yun Zhong

Wedbush

$94

Buy

66.25%

Upside

Reiterated

01/13/26

BioMarin: Sustained Double-Digit Growth Story Underpinned by Voxzogo Leadership, Advancing Rare-Disease Pipeline, and Accretive Amicus Acquisition

Phil Nadeau

TD Cowen

$120

Buy

112.24%

Upside

Reiterated

01/12/26

BioMarin: Buy Rating Reaffirmed on Strong 2025 Outlook, Promising Pipeline, and Accretive M&A

Luca Issi

RBC Capital

$66

Hold

16.73%

Upside

Reiterated

01/08/26

Analysts Conflicted on These Healthcare Names: Cormedix (NASDAQ: CRMD), BioMarin Pharmaceutical (NASDAQ: BMRN) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Joon Lee

Truist Financial

$80→$100

Buy

76.87%

Upside

Reiterated

12/23/25

Truist Financial Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Mitchell Kapoor

H.C. Wainwright

$55→$60

Hold

6.12%

Upside

Reiterated

12/22/25

BioMarin price target raised to $60 from $55 at H.C. WainwrightBioMarin price target raised to $60 from $55 at H.C. Wainwright

Jason Gerberry

Bank of America Securities

$102

Buy

80.40%

Upside

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cytokinetics (NASDAQ: CYTK)

Paul Matteis

Stifel Nicolaus

$61

Hold

7.89%

Upside

Assigned

12/19/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Pfizer (NYSE: PFE)

William Pickering

Bernstein

$88

Buy

55.64%

Upside

Reiterated

12/19/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Disc Medicine (NASDAQ: IRON) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Joseph Schwartz

Leerink Partners

$60

Hold

6.12%

Upside

Downgraded

12/03/25

BioMarin downgraded to Market Perform from Outperform at LeerinkBioMarin downgraded to Market Perform from Outperform at Leerink

Akash Tewari

Jefferies

$113

Buy

99.86%

Upside

Reiterated

10/28/25

Jefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Mohit Bansal

Wells Fargo

$90→$70

Buy

23.81%

Upside

Reiterated

10/28/25

BioMarin price target lowered to $70 from $90 at Wells FargoBioMarin price target lowered to $70 from $90 at Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months

xxx

Success Rate

15/36 ratings generated profit

Average Return

-0.41%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.41% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

21/44 ratings generated profit

Average Return

-3.35%

reiterated a buy rating 19 days ago

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 47.73% of your transactions generating a profit, with an average return of -3.35% per trade.

2 Years

xxx

Success Rate

16/44 ratings generated profit

Average Return

-3.24%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of -3.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMRN has received 22 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 86.58.

Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $0.71 with a range of $0.24 to $1.23. The previous quarter’s EPS was -$0.16. BMRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $832.03M with a range of $811.50M to $864.00M. The previous quarter’s sales results were $786.77M. BMRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year BMRN has Performed in-line its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?

Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 86.58.

What is BMRN’s upside potential, based on the analysts’ average price target?

BioMarin Pharmaceutical has 53.13% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMRN a Buy, Sell or Hold?

BioMarin Pharmaceutical has a consensus rating of Moderate Buy which is based on 8 buy ratings, 5 hold ratings and 0 sell ratings.

What is BioMarin Pharmaceutical’s price target?

The average price target for BioMarin Pharmaceutical is 86.58. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $60.00. The average price target represents 53.13% Increase from the current price of $56.54.

What do analysts say about BioMarin Pharmaceutical?

BioMarin Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of BMRN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BMRN Analyst Ratings

BMRN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioMarin Pharmaceutical

BMRN Analyst Recommendation Trends

BMRN Financial Forecast

BMRN Earnings Forecast

BMRN Sales Forecast

BMRN Stock Forecast FAQ

Detailed List of Analyst Forecasts